|
|
No (n=57) |
Yes (n=69) |
|
|
|
|
Mean ± SD (median) |
Mean ± SD (median) |
Mean ± SD (median) |
|
Age (months) (median)
|
|
48,1±72,79 (6) |
96,74±81,51 (75) |
74,73±81,11 (24) |
10,000* |
Duration of fever (median) (days) |
|
1,94±1,16
(2) |
3,21±2 (2) |
2,67±1,8 (2) |
10,000* |
Duration of cough(median) (days)
|
|
3,06±1,98
(2,5)
|
3,85±2,41 (3)
|
3,64±2,32 (3)
|
10,230
|
Duration of hospitalization(median) (days)
|
|
7,86±3,2
(8)
|
9,62±3,99 (9)
|
8,83±3,74 (8,5)
|
10,004*
|
|
|
n (%) |
n (%) |
n (%) |
|
Gender |
Female |
22 (%38,6) |
34 (%49,3) |
56 (%44,4) |
20,230 |
|
Male |
35 (%61,4) |
35 (%50,7) |
70 (%55,6) |
|
Household close contact |
No |
19 (%33,3) |
27 (%39,1) |
46
(%36,5) |
30,455 |
|
Yes |
37 (%64,9) |
42 (%60,9) |
79 (%62,7) |
|
Underlying condition |
No |
40 (%70,2) |
43 (%62,3) |
83
(%65,9) |
- |
|
Gastroesophageal reflux |
1 (%1,8) |
0 (%0) |
1 (%0,8) |
|
|
Hydronephrosis |
1 (%1,8) |
0 (%0) |
1 (%0,8) |
|
|
Prematurity |
2 (%3,5) |
1 (%1,4) |
3 (%2,4) |
|
|
Congenital heart disease |
4 (%7) |
2 (%2,9) |
6 (%4,8) |
|
|
Asthma |
1 (%1,8) |
4 (%5,8) |
5 (%4) |
|
|
Type-1 diabetes mellitus |
3 (%5,3) |
1 (%1,4) |
4 (%3,2) |
|
|
Metabolic diseases |
1 (%1,8) |
4 (%5,8) |
5 (%4) |
|
|
Congenital neutropenia |
1 (%1,8) |
1 (%1,4) |
2 (%1,6) |
|
|
Epilepsy |
0 (%0) |
2 (%2,9) |
2 (%1,6) |
|
|
Immune deficiency |
1 (%1,8) |
3 (%4,3) |
4 (%3,2) |
|
|
Chronic kidney disease |
0 (%0) |
2 (%2,9) |
2 (%1,6) |
|
|
Obesity |
0 (%0) |
2 (%2,9) |
2 (%1,6) |
|
|
Autism |
1 (%1,8) |
0 (%0) |
1 (%0,8) |
|
|
Down syndrome |
0 (%0) |
1 (%1,4) |
1 (%0,8) |
|
|
Acute lymphoblastic leukemia |
0 (%0) |
2 (%2,9) |
2 (%1,6) |
|
|
Mental retardation |
0 (%0) |
1 (%1,4) |
1 (%0,8) |
|
|
Cerebral palsy |
1 (%1,8) |
0 (%0) |
1 (%0,8) |
|
Underlying condition |
No |
40 (%70,2) |
43 (%62,3) |
83
(%65,9) |
40,461 |
|
Yes |
17 (%29,8) |
26 (%37,7) |
43 (%34,1) |
|
Symptoms |
Fever |
35 (%61,4) |
48 (%69,6) |
83 (%65,9) |
20,336 |
|
Cough |
18 (%31,6) |
48 (%69,6) |
66 (%52,4) |
40,000* |
|
Runny nose |
2 (%3,5) |
4 (%5,8) |
6 (%4,8) |
50,435 |
|
Sorethroat |
1 (%1,8) |
3 (%4,3) |
4 (%3,2) |
- |
|
Myalgia |
6 (%10,5) |
15 (%21,7) |
21 (%16,7) |
40,150 |
|
Abdominal pain |
1 (%1,8) |
4 (%5,8) |
5 (%4) |
- |
|
Diarrhoea |
9 (%15,8) |
5 (%7,2) |
14 (%11,1) |
40,217 |
|
Shortness of breath |
1 (%1,8) |
22 (%31,9) |
23 (%18,3) |
- |
Favipiravir use |
No |
55 (%96,5) |
56 (%81,2) |
111 (%88,1) |
40,018* |
|
Yes |
2 (%3,5) |
13 (%18,8) |
15 (%11,9) |
|
Azithromycin use |
No |
49 (%86) |
50 (%72,5) |
99 (%78,6) |
40,105 |
|
Yes |
8 (%14) |
19 (%27,5) |
27 (%21,4) |
|
Antibiotherapy |
No |
19 (%33,3) |
9 (%13) |
28 (%22,2) |
- |
|
Ampicillin-sulbactam |
3 (%5,3) |
2 (%2,9) |
5 (%4) |
|
|
Ampicillin+cefotaxime |
12 (%21,1) |
6 (%8,7) |
18 (%14,3) |
|
|
Ceftriaxone |
15 (%26,3) |
14 (%20,3) |
29 (%23) |
|
|
Cefotaxime |
4 (%7) |
7 (%10,1) |
11 (%8,7) |
|
|
Teicoplanin+piperacillin-tazobactam |
1 (%1,8) |
1 (%1,4) |
2
(%1,6) |
|
|
Teicoplanin+ceftriaxone |
1 (%1,8) |
24 (%34,8) |
25 (%19,8) |
|
|
Vancomycin+ceftriaxone |
1 (%1,8) |
4 (%5,8) |
5 (%4) |
|
|
Cefepime |
1 (%1,8) |
2 (%2,9) |
3 (%2,4) |
|
Type of delivery |
Spontaneous vaginal delivery |
23 (%40,4) |
42
(%60,9) |
65 (%51,6) |
20,022* |
|
Cesarean delivery |
34 (%59,6) |
27 (%39,1) |
61 (%48,4) |
|
Non-invasive mechanical ventilation |
No |
57 (%100) |
59 (%85,5) |
116 (%92,1) |
- |
|
Yes |
0 (%0) |
10 (%14,5) |
10 (%7,9) |
|
Neutropenia |
No |
42 (%73,7) |
56 (%81,2) |
98 (%77,8) |
40,430 |
|
Yes |
15 (%26,3) |
13 (%18,8) |
28 (%22,2) |
|
Lymphopenia |
No |
52 (%91,2) |
49 (%71) |
101 (%80,2) |
40,009* |
|
Yes |
5 (%8,8) |
20 (%29) |
25 (%19,8) |
|
Corticosteroid use |
No |
57 (%100) |
58 (%84,1) |
115 (%91,3) |
- |
|
Yes |
0 (%0) |
11 (%15,9) |
11 (%8,7) |
|
Low molecular–weight heparin use |
No |
53 (%93) |
52 (%75,4) |
105 (%83,3) |
40,016* |
|
Yes |
4 (%7) |
17 (%24,6) |
21 (%16,7) |
|
Mortality |
No |
56 (%98,2) |
69 (%100) |
125 (%99,2) |
- |
|
Yes |
1 (%1,8) |
0 (%0) |
1 (%0,8) |
|